Navigation Links
Scientists discover new protein involved in lung cancer
Date:2/27/2014

Scientists from The University of Manchester part of the Manchester Cancer Research Centre (MCRC) - have discovered a new protein that is involved in cancer and inflammation in lung tissue.

The findings, published in the Journal of Biological Chemistry, could help in the development of new drugs to target lung cancer.

Lung cancer is the most common cause of cancer death in Greater Manchester, with around 930 men and 790 women dying from the disease every year in the area.

While there have been major advances in treatments and outcomes for some cancers over the past 60 years, lung cancer patients have enjoyed few of these improvements and new therapies have not made a difference to their survival.

The research by the Manchester team looked at glucocorticoids, the hormones that regulate inflammation and energy production in cells in the body. In lung cancer these hormones are known to play a role in controlling cell growth.

Glucocorticoids work through receptors, and this new research reveals how these receptors work. In particular, a newly discovered enzyme, known as Merm1, was discovered to be essential for glucocorticoids to work normally. Merm1 was found to be suppressed in lung inflammation, and in cancer.

Professor David Ray, Professor of Medicine and Endocrinology at The University of Manchester who led the research, said: "We know that resistance to glucocorticoids happens in various inflammatory diseases, as well as cancer, in lung tissue. We wanted to explore whether a protein, known as Merm1, was involved in this resistance and therefore involved in controlling the uncontrolled cell growth that is the hallmark of cancer."

The study showed Merm1 controls the binding between a glucocorticoid receptor and its target genes. This step is essential for the receptor to work, and to control cell growth, and division. More importantly, it revealed that inflammation, as seen in asthma or bronchitis, results in loss of Merm1.

Professor Ray said: "This work shows that targeting Merm1 could offer a new strategy in developing anti-inflammatory treatments.

Dr Toryn Poolman, from The University of Manchester and MCRC who also worked on the research, said: "The study has given us a new insight into the mechanisms at play in lung inflammation and lung cancer. We believe it could provide a new area to target drugs in lung cancer."


'/>"/>
Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester
Source:Eurekalert

Related medicine news :

1. Scientists explore promising new option for first line of attack in lymphoma
2. Tel Aviv University scientists honored for proposals in melanoma research
3. Scientists call for screening mammography every 2 years for most women
4. NIH scientists find mechanism that helps HIV evade antibodies, stabilize key proteins
5. Scientists develop powerful new animal model for metastatic prostate cancer
6. NIH scientists map gene changes driving tumors in common pediatric soft-tissue cancer
7. Scripps Florida scientists find regulator of amyloid plaque buildup in Alzheimers disease
8. NCCS scientists discover gene regulation is dependent on protein ANP32E
9. Scientists make your stomach turn bright green if you have an ulcer
10. Scientists reduce protein crystal damage, improve pharmaceutical development
11. It's All In The Climate: New Study from Research Scientists at Florida International University Predict
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
(Date:4/28/2017)... ... 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... to and which He does not. Yisrayl says with so many titles and names ... name, but he says with a little Scripture, backed with a lot of research, the ...
(Date:4/28/2017)... ... 28, 2017 , ... Intellitec Solutions announced the publication of ... Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software package. With ... care, Brooke Grove now has the capability to achieve its goal for a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor ... leant his presence to an educational purpose as the host of the “Informed” series. ... cancer. In a recent episode, the series focuses on thyroid cancer. , Although thyroid ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology: